| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722619 | CIDARA THERAPS | Antifungal agents and uses thereof |
Mar, 2032
(7 years from now) | |
| US11654196 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2032
(7 years from now) | |
| US9526835 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| US10702573 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| US11819533 | CIDARA THERAPS | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(14 years from now) | |
| US11197909 | CIDARA THERAPS | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | CIDARA THERAPS | Dosing regimens for treatment of fungal infections |
Mar, 2037
(12 years from now) | |
Rezzayo is owned by Cidara Theraps.
Rezzayo contains Rezafungin Acetate.
Rezzayo has a total of 7 drug patents out of which 0 drug patents have expired.
Rezzayo was authorised for market use on 22 March, 2023.
Rezzayo is available in powder;intravenous dosage forms.
Rezzayo can be used as treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration.
Drug patent challenges can be filed against Rezzayo from 22 March, 2032.
The generics of Rezzayo are possible to be released after 14 July, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER;INTRAVENOUS
REZZAYO family patents
